This Small-Cap Biotech Stands Out From its Peers, Estimates Strong Sales Growth of 41% Next Year

Spotlight Growth - Penny Stocks, Small Cap Stocks, Micro-Cap and Micro Cap Stocks, Stock Exchange, NASDAQ, Crypto, BitCoin, DogeCoin, Ai, Artificial Intelligence, Chat GPT, OpenAi, Open Ai, ASURE Software, Trending, Now, Breaking News, BioTech, Data, Analytics, Technology, Big Tech, Banking, SVB, Bank Closures, Failures, Finance, Stock Market News, WeBull, RobinHood, Reddit Traders, Trading, Investing, Investors, Investment, Investments, Day Trading, Real Estate, VC, Venture Capital, Private Equity, Firm, Firms, OTC Markets, Public, Private, OTCQB, GOOG, APPLE, Shareholders, Stakeholders, Shares, Finance Education, Blog, Articles, Consumer Goods, Pharma, Commodities, Precious Metals, Gold, Silver, Cannabis, CBD, Lithium, Electric Vehicles, Solar, Tesla, Charging, EV, Cloud Computing, Wall Street Bets, Sports Betting, Economy, Economics, IPO, Trade Ideas, Intellectual Property Rights, Private Placement, Crowd Funding, Fundraising, Meta, Metaverse, Web 3, Cyber, Cybersecurity, Cyber Security, Aircraft, VPN, Yahoo Finance, Benzinga, BarChart.

The small-cap biotech sector is a favorite of growth investors, but the space can be fraught with highly volatile companies prone to wild price swings where profitability is a far-off dream. Catalyst Pharmaceuticals (NASDAQ: CPRX) represents the rare stock in the space that has a proven track record, a reasonable valuation, profitable operations, and attractive growth prospects. For investors seeking to add healthcare exposure to their portfolios, CPRX could be worth a look. The Coral Gables, FL-based Catalyst was founded in 2002 and has a market cap of $780 million.

Catalyst develops and sells therapeutics for patients with rare, chronic neuromuscular and neurological diseases and disorders. The flagship product is Firdapse, which is a proprietary phosphate treatment for people with Lambert-Eaton Myasthenic Syndrome (LEMS), myasthenia gravis, and Ruzurgi, both on the adult and pediatric sides. LEMS is a rare neuromuscular disease where the immune system attacks the body’s cells and causes a breakdown in the body’s ability to send signals to nerve and muscle cells.

Firdapse (clinical name Amifampridine) is the only evidence-based FDA-approved LEMS treatment on the market for adult patients. It is also approved by the European Medicines Agency. Catalyst also received approval for the product in Canada in 2020 and is currently working to receive approval in Japan. Firdapse improves the communications of a signal called acetylcholine (Ach) between nerves and muscles.

Turning to fundamentals, Catalyst has solid gross profitability of 85.5% and net profitability of 31.2% coupled with a price-to-earnings ratio (P/E) of 20.7. These marks compare favorably to the biotech industry averages of 74% gross margin, 5% net margin, and the industry P/E is not available due to the large number of unprofitable companies that inhabit the space.

The analyst community is bullish on CPRX with five firms publishing coverage, all with a Strong Buy rating. The positive sentiment is most likely due to the company’s robust growth prospects, a bright spot within the industry. Catalyst is forecast to grow sales by 41% next year and earnings by 77.5%, compared to the industry estimates of -11.7% for sales and -5.7% for earnings for the same period. On the valuation side, Catalyst has an EV/EBITDA of 12.4 where the industry average is 17.8, suggesting upside potential for CPRX. A profitable company that is also set up for future growth is somewhat of an anomaly in the small-cap biotech arena, so Catalyst is a positive outlier.

Catalyst Pharmaceuticals has a compelling story as they have the only FDA-approved treatment in their space. The company has twenty years of track record, a profitable product line, and is in the process of opening up new markets. The company seems reasonably valued and while it is more volatile than the overall market with a beta of 1.23, it represents an interesting opportunity for investors seeking small-cap biotech stocks to add to their holdings.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

This Small-Cap Biotech Stands Out From its Peers, Estimates Strong Sales Growth of 41% Next Year

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

Vision Marine (NASDAQ: VMAR): An Innovative, Revenue-Producing Company Riding the Electric Boating Growth Trend

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

Telcoin (TEL) Continues to Demonstrate Fundamental Progress, Displaying Bullish Technical Setup

Grove Collaborative (NYSE: GROV) Expands Retail Distribution Footprint Into 2,200 Additional Stores

The Metaverse is Exploding in Popularity and Growth

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

Safe-T Group Ltd. (NASDAQ: SFET) to Participate at A.G.P.’s Virtual Emerging Growth Technology Conference on February 4, 2021

Nvidia Announces New Chip Specifically For Ethereum Mining

Sortis Holdings, Inc. (OTC Pink: SOHI) Announces Results for Second Quarter 2020

Medical Marijuana Coming Soon to Virginia

SushiSwap (SUSHI) Appropriates Uniswap’s Liquidity Pool by Preempting Native Token Release

Europe Shows Signs of Warming to SPACs

Singapore’s Journey to Becoming a Biotech Powerhouse

SeaStar Medical (NASDAQ: ICU) Earns Third FDA Breakthrough Device Designation for Selective Cytopheretic Device

Exploring What Led to a 3,000% Surge in Shares of Tempest Therapeutics (NASDAQ: TPST)

Vivos Therapeutics (NASDAQ: VVOS) Secures Strategic Alliances to Enhance Clear Aligner Offerings and Bolster Revenue Streams

Shares of Soleno Therapeutics (NASDAQ: SLNO) Surge Over 500% After Its DCCR Candidate Shows Promise in PWS Clinical Trials

Understanding EBITDA and Adjusted EBITDA: A View Into Asure’s (NASDAQ: ASUR) Recent Financial Performance

From Microsoft to Travel Tech: VCI Global’s (NASDAQ: VCIG) Expanding AI Horizons

Singapore’s Leap into the Future of Cell and Gene Therapies

Asure (NASDAQ: ASUR) Completes Capital Raise to Fuel High-Interest Debt Reduction, Craig-Hallum Analyst Praises Move and Estimates Bullish Outcome

Asure (NASDAQ: ASUR) Reports Massive 50% Y/Y Revenue Growth During Q2 2023, Raises $40 Million to Pay Off High-Interest Debt and Fund Acquisitions

Recent News

Singapore’s Journey to Becoming a Biotech Powerhouse

SeaStar Medical (NASDAQ: ICU) Earns Third FDA Breakthrough Device Designation for Selective Cytopheretic Device

Categories

Site Navigation